caterina casari
- Hémostase, Inflammation, Thrombose (HITH - U1176 Inserm - CHU Bicêtre)
Présentation
I am a tenured researcher in France at the Inserm Unit 1176, Hemostasis, Inflammation and Thrombosis laboratory. My research studies focus on von Willebrand factor and its partners. I am interested in developing in vitro & in vivo models to elucidate molecular mechanisms underlying unsolved clinical aspects of congenital and acquired von Willebrand disease. I am also interested in exploring new therapeutic approaches for VWF-associated disorders.
Domaines de recherche
Publications
Publications
|
|
MADDlessness may cause von Willebrand disease type 12025, pp.2020-2022. ⟨10.1182/blood.2025030528⟩ |
|
|
Impact of the COVID‐19 pandemic on education and clinical training2021, pp.2099-2100. ⟨10.1111/jth.15470⟩ |
|
|
Exciting times for the ISTH early career professionals2020, pp.2437-2438. ⟨10.1111/jth.15070⟩ |
Novel VWD TreatmentWFH Comprehensive Core Summit, Apr 2025, Dubai, United Arab Emirates. Haemophilia, 2025, ⟨10.1111/hae.70031⟩ |
|
|
|
OC 10.3 Platelets mediate intracranial aneurysm formation and rupture in miceInternational Society of Thrombosis and Haemostasis ISTH, Research and Practice in Thrombosis and Haemostasis, 7, pp.100581, 2023, ⟨10.1016/j.rpth.2023.100581⟩ |
|
|
OC 13.1 Shear-induced Platelet-GPIbα Shedding under Extracorporeal Membrane Oxygenation Promotes Thrombocytopenia Independently from von Willebrand FactorInternational Society of Thrombosis and Haemostasis ISTH, Research and Practice in Thrombosis and Haemostasis, 5, pp.e12591, 2021, ⟨10.1002/rth2.12591⟩ |
|
|
Design and Characterization of FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate61 ASH Annual Meeting, Blood, 134 (Supplement_1), pp.4638-4638, 2019, ⟨10.1182/blood-2019-128490⟩ |
|
|
OC 56.5 In vitro and in vivo Amelioration of the von Willebrand Disease Type 2B Phenotype Using an Allele-specific siRNAInternational Society of Thrombosis and Haemostasis ISTH, Research and Practice in Thrombosis and Haemostasis, 3, pp.1-228, 2019, ⟨10.1002/rth2.12227⟩ |
A consistent in vivo factor VIII-equivalence is unlikely to exist for non-factor therapiesCongrès Français d'Hémostase, Société Française de Thrombose et d'Hémostase, Sep 2024, Lille, France |
|
Fitusiran-treatment modulates the ratio between alpha- and beta-antithrombin isoformsCongrès Français d'Hémostase, Société Française de Thrombose et d'Hémostase, Sep 2024, Lille, France |
|
Experimental and clinical rationale for the use of bispecific antibodies in von Willebrand diseaseBari International Conference BIC, Sep 2023, Palerme, Italy |
|
|
|
Future therapies for von Willebrand disease16th European Association for Haemophilia and Allied Disorders (EAHAD), Feb 2023, Manchester, United Kingdom. pp.5-13, ⟨10.1111/hae.14713⟩ |
|
|
Novel Therapeutics for VWDInternational Society of Thrombosis and Haemostasis ISTH, Jun 2023, Montreal, Canada. ⟨10.1016/j.rpth.2023.100193⟩ |
Update on KB-V13A12 & SynthoPlatesEHC Workshop in New technologies in rare bleeding disorders, Nov 2023, Cascais, Portugal |
|
Antibodies for VWDEHC Workshop in New technologies in rare bleeding disorders, Nov 2023, Cascais, Portugal |
|
KB-V13A12, a novel nanobody-based therapeutic molecule for the treatment of von Willebrand diseaseCongrès Français d’Hémostase (CFH), May 2023, St Malo, France |
|
|
|
KB-V13A12, a novel nanobody-based therapeutic molecule for the treatment of von Willebrand diseaseInternational Society of Thrombosis and Haemostasis ISTH, Jun 2023, Montreal, Canada. ⟨10.1016/j.rpth.2023.100545⟩ |
Emicizumab ameliorates heamostasis in a von Willebrand Disease-type 3 murine modelCongrès Français d’Hémostase (CFH), May 2023, St Malo, France |
|
Bon vent pour les patients avec la maladie de Willebrand?Congrès Français d’Hémostase (CFH), May 2023, St Malo, France |
|
Antibody-based strategies as potential new treatments for von Willebrand Disease65th ASH Annual Meeting, Dec 2023, San Diego, United States |
|
|
|
OC 22.4 Unique humanized mouse models of von Willebrand disease to implement the need for innovative therapeutic strategiesInternational Society of Thrombosis and Haemostasis ISTH, Jul 2022, London, United Kingdom. pp.e12787, ⟨10.1002/rth2.12787⟩ |
|
|
OC 43.5 Domain-specific nanobodies distinguish intact and proteolyzed forms of von Willebrand factor in congenital von Willebrand diseaseInternational Society of Thrombosis and Haemostasis ISTH, Jul 2022, London, United Kingdom. ⟨10.1002/rth2.12787⟩ |
Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated miceCongrès Français d’Hémostase (CFH), Jun 2022, Bordeaux, France |
|
|
|
OC 50.4 Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated miceInternational Society of Thrombosis and Haemostasis ISTH, Jul 2022, London, United Kingdom. ⟨10.1002/rth2.12787⟩ |
Tailored treatments for VWDEHC Annual Conference, Oct 2021, Virtual conference, Belgium |
|
Future therapies in von Willebrand disease: time for a tailored fit?Bari International Conference BIC, Sep 2021, Venezia, Italy |
|
New Treatment Options for VWDInternational Society of Thrombosis and Haemostasis ISTH, Jul 2021, Philadelphia - online, United States |
|
Vecchi e nuovi percorsi del bus molecolare: il fattore di von WillebrandXXVI SISET, Nov 2020, Baveno - online, Italy |
|
Dégradation du facteur Willebrand et syndrome de Willebrand acquis: Utilisation des dispositifs de support mécaniqueGFHT 2019, Sep 2019, Montpellier, France |
|
SFF 1.2 In vitro and in vivo modulation of von Willebrand factor gene mutations with dominant-negative effectEuropean Congress on Thrombosis and Haemostasis ECTH, Oct 2019, Glasgow, United Kingdom |
|
|
Von Willebrand disease: from pathophysiology to new therapeutic optionsLife Sciences [q-bio]. University Paris-Saclay, 2022 |